MX2022006737A - Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados. - Google Patents

Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados.

Info

Publication number
MX2022006737A
MX2022006737A MX2022006737A MX2022006737A MX2022006737A MX 2022006737 A MX2022006737 A MX 2022006737A MX 2022006737 A MX2022006737 A MX 2022006737A MX 2022006737 A MX2022006737 A MX 2022006737A MX 2022006737 A MX2022006737 A MX 2022006737A
Authority
MX
Mexico
Prior art keywords
peptide
gip
dependent insulinotropic
glucose
optimized
Prior art date
Application number
MX2022006737A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Hovard Sparre-Ulrich
Ditte Riber
Mette Marie Rosenkilde
Samra Joke Sanni
Original Assignee
Antag Therapeutics Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2019/083506 external-priority patent/WO2020115048A1/en
Application filed by Antag Therapeutics Aps filed Critical Antag Therapeutics Aps
Publication of MX2022006737A publication Critical patent/MX2022006737A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2022006737A 2019-12-03 2020-12-03 Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados. MX2022006737A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues
EP20179259 2020-06-10
PCT/EP2020/084487 WO2021110845A1 (en) 2019-12-03 2020-12-03 Optimized gip peptide analogues

Publications (1)

Publication Number Publication Date
MX2022006737A true MX2022006737A (es) 2022-06-14

Family

ID=71083547

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006737A MX2022006737A (es) 2019-12-03 2020-12-03 Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados.

Country Status (10)

Country Link
US (1) US20250346647A2 (cg-RX-API-DMAC7.html)
EP (1) EP4069719A1 (cg-RX-API-DMAC7.html)
JP (2) JP7788376B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220108064A (cg-RX-API-DMAC7.html)
CN (2) CN122520749A (cg-RX-API-DMAC7.html)
AU (1) AU2020398675A1 (cg-RX-API-DMAC7.html)
CA (1) CA3157387A1 (cg-RX-API-DMAC7.html)
IL (1) IL293249A (cg-RX-API-DMAC7.html)
MX (1) MX2022006737A (cg-RX-API-DMAC7.html)
WO (1) WO2021110845A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023014740A (es) * 2021-06-10 2024-03-13 Antag Therapeutics Aps Tratamiento de la obesidad y trastornos relacionados con la obesidad.
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
CN117402219B (zh) 2022-07-13 2024-07-30 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
AR134436A1 (es) * 2023-11-22 2026-01-14 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Uso de un agonista dual glp-1r / gipr en la fabricación de un medicamento veterinario
TW202615088A (zh) * 2024-06-14 2026-04-16 美商美國禮來大藥廠 用於改善胰島素敏感性之組合物及方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101155828A (zh) * 2005-02-11 2008-04-02 安米林药品公司 Gip类似物和具有可选择性质的杂合多肽
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CA2597649A1 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
JP5399244B2 (ja) * 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド
CA2732949C (en) * 2008-08-07 2016-12-20 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
ES2574835T3 (es) * 2008-08-07 2016-06-22 Ipsen Pharma S.A.S. Análogos del polipéptido insulinotrópico dependiente de glucosa
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
CN103003300B (zh) * 2010-04-27 2017-06-09 西兰制药公司 Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
CA2872314C (en) * 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2016034186A1 (en) 2014-09-05 2016-03-10 University Of Copenhagen Gip peptide analogues
US11572399B2 (en) * 2017-05-31 2023-02-07 University Of Copenhagen Long-acting GIP peptide analogues
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
US12187773B2 (en) * 2018-12-03 2025-01-07 Antag Therapeutics Aps Modified GIP peptide analogues

Also Published As

Publication number Publication date
US20250346647A2 (en) 2025-11-13
US20230416330A1 (en) 2023-12-28
JP2023505441A (ja) 2023-02-09
CN122520749A (zh) 2026-08-07
JP2025172864A (ja) 2025-11-26
IL293249A (en) 2022-07-01
CN114761420B (zh) 2026-04-28
CA3157387A1 (en) 2021-06-10
JP7788376B2 (ja) 2025-12-18
KR20220108064A (ko) 2022-08-02
EP4069719A1 (en) 2022-10-12
AU2020398675A1 (en) 2022-05-26
CN114761420A (zh) 2022-07-15
WO2021110845A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
MX2021006505A (es) Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) modificados.
CY1125359T1 (el) Νεα υποκατεστημενα με 6-6 δικυκλικο αρωματικο δακτυλιο νουκλεοσιδικα αναλογα για χρηση ως αναστολεις prmt5
PE20210162A1 (es) Analogos de incretina y sus usos
CL2020002034A1 (es) Agonista triple de receptores de glucagón/glp-1/gip. (divisional solicitud 201801776)
CY1121032T1 (el) Παραγωγα εξενδινης-4 ως επιλεκτικοι αγωνιστες υποδοχεα γλυκαγονης
CL2019002297A1 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
MX2017015105A (es) Compuestos del peptido yy (pyy) selectivos y sus usos.
PH12019502252A1 (en) Gip receptor activating peptide
DK4122954T3 (da) Novel GLP-1-analoger
MX390698B (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
BR112019025195A8 (pt) análogos do peptídeo gip de ação prolongada
MX2017004559A (es) Receptores de celulas t.
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
MX2023002450A (es) Formulaciones farmaceuticas para tratar la endometriosis, los fibromas uterinos, el sindrome de ovario poliquistico o la adenomiosis.
IL285547A (en) Long-acting glp-2 analogs
CL2018003121A1 (es) Inhibidores del potenciador del homólogo zeste 2.
CU20210099A7 (es) Anticuerpos de receptor de péptido natriurético 1
EA201790896A1 (ru) Пролекарства фенольных агонистов trpv1
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
CL2022001227A1 (es) Agonistas del receptor npy2
EA201792156A1 (ru) Ксантинзамещенные алкинилкарбаматы/обращенные карбаматы в качестве антагонистов a
DK3886813T3 (da) Farmaceutiske formuleringer af cyclosporinanaloger